- Home
- TERN vs SIGA Comparison
TERN vs SIGA Comparison
Compare TERN & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- SIGA
- Stock Information
- Founded
- TERN 2017
- SIGA 1995
- Country
- TERN United States
- SIGA United States
- Employees
- TERN N/A
- SIGA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- SIGA Health Care
- Exchange
- TERN Nasdaq
- SIGA Nasdaq
- Market Cap
- TERN 634.5M
- SIGA 515.1M
- IPO Year
- TERN 2021
- SIGA 1997
- Fundamental
- Price
- TERN $8.30
- SIGA $8.28
- Analyst Decision
- TERN Buy
- SIGA
- Analyst Count
- TERN 6
- SIGA 0
- Target Price
- TERN $13.99
- SIGA N/A
- AVG Volume (30 Days)
- TERN 1.0M
- SIGA 479.2K
- Earning Date
- TERN 11-11-2025
- SIGA 11-06-2025
- Dividend Yield
- TERN N/A
- SIGA 7.11%
- EPS Growth
- TERN N/A
- SIGA N/A
- EPS
- TERN N/A
- SIGA 1.14
- Revenue
- TERN N/A
- SIGA $179,639,422.00
- Revenue This Year
- TERN N/A
- SIGA N/A
- Revenue Next Year
- TERN N/A
- SIGA $115.06
- P/E Ratio
- TERN N/A
- SIGA $7.27
- Revenue Growth
- TERN N/A
- SIGA 3.86
- 52 Week Low
- TERN $1.87
- SIGA $4.95
- 52 Week High
- TERN $8.78
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- TERN 57.97
- SIGA 46.70
- Support Level
- TERN $7.45
- SIGA $8.15
- Resistance Level
- TERN $8.77
- SIGA $9.29
- Average True Range (ATR)
- TERN 0.41
- SIGA 0.34
- MACD
- TERN -0.00
- SIGA -0.11
- Stochastic Oscillator
- TERN 51.36
- SIGA 24.62
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.